Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy

Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):109-116. doi: 10.1016/j.bbcan.2017.02.007. Epub 2017 Mar 1.

Abstract

Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit growth of different types of malignancies. Additionally, this multifaceted RTK inhibitor was reported to be a tumor suppressor, a stem cell regulator, and a modulator of different cellular phenotypes. This mini-review provides a concise and up-to-date summary about the known functions of LRIG1 and its related family members, with a special emphasis on underlying molecular mechanisms and the opportunities for harnessing its therapeutic potential against cancer.

Keywords: Cancer; Ectodomain; Leucine-rich repeats and immunoglobulin-like domains containing protein 1; Nervous system; Receptor tyrosine kinase.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cell Proliferation / drug effects
  • Humans
  • Membrane Glycoproteins / metabolism*
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use*
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*

Substances

  • Membrane Glycoproteins
  • Protein Kinase Inhibitors
  • Receptor Protein-Tyrosine Kinases